Wilson Mark Andrew
Chief Legal Officer
Wilson Mark Andrew has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Nov 25, 2025.
On the most recent filing, Wilson Mark Andrew is listed as Chief Legal Officer at NEKTAR THERAPEUTICS. Inside the rolling window, Wilson Mark Andrew reported no open-market purchases and 1 open-market sale totaling $34K in NKTR.
Companies traded
Other insiders at NKTR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$34K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Wilson Mark Andrew made?
Wilson Mark Andrew has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2025.
Which companies does Wilson Mark Andrew trade?
Wilson Mark Andrew has filed SEC Form 4 disclosures for 1 company, including NKTR.
When was Wilson Mark Andrew's most recent SEC Form 4 filing?
Wilson Mark Andrew's most recent SEC Form 4 filing on Tracefour is dated Nov 25, 2025.
What is Wilson Mark Andrew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Wilson Mark Andrew is listed as Chief Legal Officer.
What is Wilson Mark Andrew's total buy and sell value in the current window?
Inside the rolling retention window, Wilson Mark Andrew bought $0 and sold $34K based on SEC Form 4 filings.
What was Wilson Mark Andrew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 630 NKTR shares on 2025-11-25, worth $34K, per SEC Form 4 filings.